This article has no abstract; the first 100 words appear below.

Asthma and lower respiratory infections are leading causes of morbidity and mortality in pediatric populations. Thus, having low-cost, effective, safe options for prevention could have important implications for both clinical practice and public health. In this issue of the Journal, Bisgaard and et al.1 report that high-dose supplementation of the n−3 polyunsaturated fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) derived from fish oil in the third trimester of pregnancy significantly decreased the risk of persistent wheeze and asthma (the primary outcome) during the first 5 years of a child’s life. The intervention also decreased the rate of lower . . .